New drug nearly doubles survival rates in some pancreatic cancer patients, study says
Summary
A new drug called daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer, according to a recent study. The medication, taken as a daily pill, showed better results and fewer side effects than standard chemotherapy.Key Facts
- Daraxonrasib targets a mutated protein that helps pancreatic tumors grow in over 90% of cases.
- The study involved 500 patients with metastatic pancreatic cancer whose cancer stopped responding to prior treatment.
- Patients on daraxonrasib lived a median of 13.2 months compared to 6.7 months for those on chemotherapy.
- The drug reduced the risk of death by 60% compared to standard chemotherapy.
- Patients taking daraxonrasib reported fewer severe side effects and better quality of life.
- The FDA plans to speed up the review process and allows some patients to access the drug early through an expanded access program.
- The drug’s maker funded the study, and researchers suggest it could become the new standard treatment for this type of cancer.
- Public figures like former Senator Ben Sasse have spoken about receiving relief from the drug.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
